The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations c…

Acute Myeloid Leukemias

~Estimated

~$10 – $8,750

Syndax PharmaceuticalsNCT07211958

Phase 1

A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients With Advanced Hematologic Malignancies

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced …

Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia (CMML)Chronic Myelomonocytic Leukemia-1+9 more

~Estimated

~$10 – $8,750

Solu Therapeutics, IncNCT06950034